Briacell Therapeutics Corp. (BCTXF) 0.1571 $BCTXF
BriaCell Appoints New York-Based RK Equity Advisors and TrueNorth Lifesciences as Corporate Advisor
Marketwire Canada - Thu Sep 15, 7:30AM CDT
BERKELEY, CA and VANCOUVER, BC--(Marketwired - September 15, 2016) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company"
(TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce that it has entered into an agreement (the "Agreement" with RK Equity Advisors LLC and TrueNorth Lifesciences LLC ("RK TrueNorth" for the provision of corporate advisory services. The Agreement is effective until September 30, 2017 and is subject to the approval of the TSX Venture Exchange (the "TSXV".
BCT.VN: 0.190 (+0.005)
BriaCell Appoints the Lead Principal Investigator and First Clinical Site for Its Upcoming Phase I/IIa Clinical Trial in Advanced Breast Cancer
Marketwire Canada - Wed Aug 17, 7:30AM CDT
Dr. Jarrod P. Holmes, a Prominent Breast Cancer Vaccine Expert to Lead the Study out of St. Joseph Health-Sonoma County
BCT.VN: 0.190 (+0.005)
BriaCell Appoints Contract Research Organization, Cancer Insight, to Manage Its Upcoming Phase I/IIa Clinical Trials in Advanced Breast Cancer
Marketwired - Wed May 18, 7:30AM CDT
BERKELEY, CA and VANCOUVER, BC--(Marketwired - May 18, 2016) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company" (TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce that it has signed a definitive agreement with Cancer Insight, LLC, a cancer-vaccine focused clinical research organization (CRO), to initiate Phase I/IIa clinical studies and regulatory filings for BriaVax™, its lead vaccine candidate for the treatment of advanced breast cancer. According to the agreement, BriaCell will sponsor the clinical trial which will evaluate the safety and efficacy of BriaVax™, a novel vaccine, for the treatment of advanced breast cancer, and Cancer Insight will provide clinical and regulatory affairs management services for the entire trial.
BCT.VN: 0.190 (+0.005)
BriaCell Adds U.S. Biotech Veteran to Its Board of Directors
Marketwired - Tue May 10, 7:31AM CDT
BERKELEY, CA and VANCOUVER, BC--(Marketwired - May 10, 2016) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company" (TSX VENTURE: BCT)(OTCQB: BCTXF) today announced a change to its board of directors.
BSX: 23.38 (-0.13), BCT.VN: 0.190 (+0.005)
BriaCell Completes Previously Announced Investment With Leading U.S. Biotech Fund and Non-Brokered Private Placement
Marketwired - Tue May 03, 7:31AM CDT
BriaCell Therapeutics Corp. ("BriaCell" or the "Company" (TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce that the Company has completed both its previously announced brokered and non-brokered private placements of units totaling gross proceeds of C$1,275,000.
BCT.VN: 0.190 (+0.005)
BriaCell Files a Patent Application to Protect Additional Cancer Vaccines With Genetic Features Thought to Promote Strong Anti-Tumor Activity
Marketwired - Tue Apr 12, 7:30AM CDT
BriaCell Therapeutics Corp. ("BriaCell" or the "Company" (TSX VENTURE: BCT) (OTCQB: BCTXF) is very pleased to announce that it has filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) outlining certain features thought to improve clinical efficacy of whole-cell cancer vaccines.
BCT.VN: 0.190 (+0.005)
IIROC Trade Resumption - BriaCell Therapeutics Corp.
Newsfile Corp - Wed Nov 04, 10:08AM CST
Trading resumes in:
BriaCell Receives FDA Authorization to Initiate Phase I/IIa Trial of Cell-Based Immunotherapy BriaVax(TM) in Advanced Breast Cancer Patients
Marketwired - Wed Nov 04, 10:02AM CST
BriaCell Therapeutics Corp (OTCQB: BCTXF) (TSX VENTURE: BCT) ("BriaCell", the "Company", or "BCT" is pleased to announce that the U.S. Food and Drug Administration (FDA) has given final clearance for the Company's Investigational New Drug (IND) application to initiate a Phase I/IIa clinical trial of BriaVax(TM). The open-label, non-randomized trial will enroll up to 24 breast cancer patients with advanced stages of disease. The clinical trial protocol has the provision to allow testing of the vaccine in selected patients with other cancers as well, including prostate, ovarian, pancreas, lung and bladder cancers among others. Patient enrollment is expected to begin in late 2015 or early 2016, pending the approval by the Principal Investigator's Institutional Review Board (IRB) and the execution of a final Clinical Trial Agreement with the initial clinical trial site.
BCT.VN: 0.190 (+0.005)
IIROC Trade Halt - BriaCell Therapeutics Corp.
Newsfile Corp - Wed Nov 04, 8:37AM CST
The following issues have been halted by IIROC:
IIROC Trading Halt - BCT
CNW Group - Wed Nov 04, 8:27AM CST
The following issues have been halted by IIROC:
BCT.VN: 0.190 (+0.005)
BriaCell Therapeutics to Present at 14th Annual BIO Investor Forum in San Francisco
Marketwired - Mon Oct 19, 8:30AM CDT
BriaCell Therapeutics Corp (OTCQB: BCTXF) (TSX VENTURE: BCT) ("BriaCell", the "Company", or "BCT" an immuno-oncology company focused on the development of novel cancer treatments, today announced that the Company will present at the 14th Annual BIO Investor Forum in San Francisco, California on Tuesday October 20th, 2015 at 9:30AM Pacific Time (12:30PM Eastern Time). Joseph Wagner, Ph.D., BriaCell's President and Chief Executive Officer, will provide an update on the manufacturing and clinical development of BriaCell's lead immuno-oncology product, BriaVax(TM).
BCT.VN: 0.190 (+0.005)
BriaCell Therapeutics Successfully Advances Towards Initiation of BriaVax(TM) Phase I/IIa Clinical Trial
Marketwired - Thu Oct 08, 8:30AM CDT
BriaCell Therapeutics Corp (OTCQB: BCTXF) (TSX VENTURE: BCT) ("BriaCell", the "Company", or "BCT" is pleased to announce that the Company has successfully advanced to the final stages of preparation for the upcoming Phase I/IIa study of BriaVax(TM).
BCT.VN: 0.190 (+0.005)
BriaCell Appoints New York-Based RK Equity Advisors and TrueNorth Lifesciences as Corporate Advisor
Marketwire Canada - Thu Sep 15, 7:30AM CDT
BERKELEY, CA and VANCOUVER, BC--(Marketwired - September 15, 2016) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company"
(TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce that it has entered into an agreement (the "Agreement" with RK Equity Advisors LLC and TrueNorth Lifesciences LLC ("RK TrueNorth" for the provision of corporate advisory services. The Agreement is effective until September 30, 2017 and is subject to the approval of the TSX Venture Exchange (the "TSXV". BCT.VN: 0.190 (+0.005)
BriaCell Appoints the Lead Principal Investigator and First Clinical Site for Its Upcoming Phase I/IIa Clinical Trial in Advanced Breast Cancer
Marketwire Canada - Wed Aug 17, 7:30AM CDT
Dr. Jarrod P. Holmes, a Prominent Breast Cancer Vaccine Expert to Lead the Study out of St. Joseph Health-Sonoma County
BCT.VN: 0.190 (+0.005)
BriaCell Appoints Contract Research Organization, Cancer Insight, to Manage Its Upcoming Phase I/IIa Clinical Trials in Advanced Breast Cancer
Marketwired - Wed May 18, 7:30AM CDT
BERKELEY, CA and VANCOUVER, BC--(Marketwired - May 18, 2016) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company"
(TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce that it has signed a definitive agreement with Cancer Insight, LLC, a cancer-vaccine focused clinical research organization (CRO), to initiate Phase I/IIa clinical studies and regulatory filings for BriaVax™, its lead vaccine candidate for the treatment of advanced breast cancer. According to the agreement, BriaCell will sponsor the clinical trial which will evaluate the safety and efficacy of BriaVax™, a novel vaccine, for the treatment of advanced breast cancer, and Cancer Insight will provide clinical and regulatory affairs management services for the entire trial. BCT.VN: 0.190 (+0.005)
BriaCell Adds U.S. Biotech Veteran to Its Board of Directors
Marketwired - Tue May 10, 7:31AM CDT
BERKELEY, CA and VANCOUVER, BC--(Marketwired - May 10, 2016) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company"
(TSX VENTURE: BCT)(OTCQB: BCTXF) today announced a change to its board of directors. BSX: 23.38 (-0.13), BCT.VN: 0.190 (+0.005)
BriaCell Completes Previously Announced Investment With Leading U.S. Biotech Fund and Non-Brokered Private Placement
Marketwired - Tue May 03, 7:31AM CDT
BriaCell Therapeutics Corp. ("BriaCell" or the "Company"
(TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce that the Company has completed both its previously announced brokered and non-brokered private placements of units totaling gross proceeds of C$1,275,000. BCT.VN: 0.190 (+0.005)
BriaCell Files a Patent Application to Protect Additional Cancer Vaccines With Genetic Features Thought to Promote Strong Anti-Tumor Activity
Marketwired - Tue Apr 12, 7:30AM CDT
BriaCell Therapeutics Corp. ("BriaCell" or the "Company"
(TSX VENTURE: BCT) (OTCQB: BCTXF) is very pleased to announce that it has filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) outlining certain features thought to improve clinical efficacy of whole-cell cancer vaccines. BCT.VN: 0.190 (+0.005)
IIROC Trade Resumption - BriaCell Therapeutics Corp.
Newsfile Corp - Wed Nov 04, 10:08AM CST
Trading resumes in:
BriaCell Receives FDA Authorization to Initiate Phase I/IIa Trial of Cell-Based Immunotherapy BriaVax(TM) in Advanced Breast Cancer Patients
Marketwired - Wed Nov 04, 10:02AM CST
BriaCell Therapeutics Corp (OTCQB: BCTXF) (TSX VENTURE: BCT) ("BriaCell", the "Company", or "BCT"
is pleased to announce that the U.S. Food and Drug Administration (FDA) has given final clearance for the Company's Investigational New Drug (IND) application to initiate a Phase I/IIa clinical trial of BriaVax(TM). The open-label, non-randomized trial will enroll up to 24 breast cancer patients with advanced stages of disease. The clinical trial protocol has the provision to allow testing of the vaccine in selected patients with other cancers as well, including prostate, ovarian, pancreas, lung and bladder cancers among others. Patient enrollment is expected to begin in late 2015 or early 2016, pending the approval by the Principal Investigator's Institutional Review Board (IRB) and the execution of a final Clinical Trial Agreement with the initial clinical trial site. BCT.VN: 0.190 (+0.005)
IIROC Trade Halt - BriaCell Therapeutics Corp.
Newsfile Corp - Wed Nov 04, 8:37AM CST
The following issues have been halted by IIROC:
IIROC Trading Halt - BCT
CNW Group - Wed Nov 04, 8:27AM CST
The following issues have been halted by IIROC:
BCT.VN: 0.190 (+0.005)
BriaCell Therapeutics to Present at 14th Annual BIO Investor Forum in San Francisco
Marketwired - Mon Oct 19, 8:30AM CDT
BriaCell Therapeutics Corp (OTCQB: BCTXF) (TSX VENTURE: BCT) ("BriaCell", the "Company", or "BCT"
an immuno-oncology company focused on the development of novel cancer treatments, today announced that the Company will present at the 14th Annual BIO Investor Forum in San Francisco, California on Tuesday October 20th, 2015 at 9:30AM Pacific Time (12:30PM Eastern Time). Joseph Wagner, Ph.D., BriaCell's President and Chief Executive Officer, will provide an update on the manufacturing and clinical development of BriaCell's lead immuno-oncology product, BriaVax(TM). BCT.VN: 0.190 (+0.005)
BriaCell Therapeutics Successfully Advances Towards Initiation of BriaVax(TM) Phase I/IIa Clinical Trial
Marketwired - Thu Oct 08, 8:30AM CDT
BriaCell Therapeutics Corp (OTCQB: BCTXF) (TSX VENTURE: BCT) ("BriaCell", the "Company", or "BCT"
is pleased to announce that the Company has successfully advanced to the final stages of preparation for the upcoming Phase I/IIa study of BriaVax(TM). BCT.VN: 0.190 (+0.005)
